DNAnexus Launches Platform-as-a-Service for Growing NGS-Based Diagnostics Market

DNAnexus Launches Platform-as-a-Service for Growing NGS-Based Diagnostics Market
Company's expertise in genomics, bioinformatics, and cloud computing accelerates the scale-up of enterprise infrastructures for analyzing and managing DNA data in clinical settings
September 16, 2013 08:00 AM Eastern Daylight Time
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DNAnexus, a pioneer in cloud-based DNA data management and analysis solutions, today announced a specialized platform-as-a-service (PaaS) designed to eliminate the common challenges and costs that enterprises face when building clinically compliant analysis pipelines for next-generation sequencing (NGS) data. DNAnexus provides a configurable API-based platform that enables clinical testing labs to efficiently move their analysis pipelines into the cloud, using their own algorithms alongside industry-recognized tools and resources to create customized workflows in a secure and compliant environment.

"The DNAnexus platform is well-suited for rapid pipeline development and enterprise-readiness. We have relied heavily on their expertise in cloud-based solutions and benefited from their experience in managing data in a clinically appropriate manner."

"DNAnexus has leveraged its years of experience in cloud-based technologies to develop a unique enterprise solution that eliminates the many headaches and capital costs that burden labs when rolling out traditional, on-premise data centers," said Andreas Sundquist, Chief Technology Officer and co-founder of DNAnexus. "Not only has our engineering team focused on building a robust and industrial-scale platform, but we have also addressed security and compliance to ensure that the DNAnexus solution meets HIPAA, CLIA, and other complex regulatory requirements related to utilizing DNA-based information in a healthcare environment."

Genomic data has only recently been introduced to the clinical setting, and as demand for patient testing soars, diagnostics companies that have traditionally used on-premise solutions are facing increasing challenges to scale their resources while meeting HIPAA and other regulatory requirements.

An early adopter of the DNAnexus solution is Boris Bastian, M.D., Ph.D., professor at the University of California, San Francisco School of Medicine. In his lab, Dr. Bastian is leading research focused on understanding the genetic alterations involved in skin cancer pathogenesis and predisposition as well as their potential role as biomarkers to improve diagnosis and treatment choice.

"Working with the DNAnexus team has been invaluable for us as we deploy our data analysis pipeline to the cloud and work toward a production-grade clinical test," said Dr. Bastian. "The DNAnexus platform is well-suited for rapid pipeline development and enterprise-readiness. We have relied heavily on their expertise in cloud-based solutions and benefited from their experience in managing data in a clinically appropriate manner."

The DNAnexus platform enables genomic R&D enterprises to easily expand their data analysis and storage infrastructure needs into the cloud and to transform large capital expenditures into transparent operating expenses. Using DNAnexus, labs of any size can build and run their data analysis apps and workflows from anywhere in the world, and work securely with research and clinical collaborators.

For more information, please visit www.dnanexus.com.

About DNAnexus

DNAnexus is powering the genomics revolution with an enterprise-level solution that combines cloud computing with advanced bioinformatics. The DNAnexus team is made up of experts in software, computational biology, and genetics who are on a mission to establish DNAnexus at the center of a growing ecosystem of scientific and clinical research, and diagnostic efforts in personalized medicine. For more information please visit https://dnanexus.com.

Contacts
For DNAnexus
Colin Sanford, 203-340-2441
[email protected]

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.